Biosimilars: It's not as simple as cost alone

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 459-464

  Roger, S D ^a   Goldsmith, D ^b  

^a GOSFORD HOSPITAL   (Australia)

^b Renal Unit   (United Kingdom)

Author keywords

Biopharmaceuticals; Biosimilars; Costs; Generics; Safety

Indexed keywords

BIOSIMILAR DRUG; GENERIC DRUG; NEW DRUG; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; NOTE;

BIOLOGICAL PRODUCTS; COST SAVINGS; DRUG APPROVAL; DRUG COSTS; DRUGS, GENERIC; EPOETIN ALFA; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; RED-CELL APLASIA, PURE; THERAPEUTIC EQUIVALENCY;

EID: 52049105653     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00942.x     Document Type: Note

References (24)

1. Anonymous (1997) Journal club on the web: bioequivalence of generic and brand-name levothyroxine. Available at: http://www.journalclub.org/vol2/a47.html (accessed 3 March 2008).
2. Harris J (2006) Marketing and globalizing biosimilars in a competitive landscape. Journal of Generic Medicine, 3 (2 115 120.
3. Park SS, Deechongkit S, Patel K et al. (2007) Analytical comparisons of certain erythropoietin products from Asia and Amgen's epoetin alfa. Abstract M-PO-0592. World Congress of Nephrology, April 21-25 2007, Rio de Janeiro, Brazil. Available at: http://www.wcn2007.org/pdf/WCN2007BooksofAbstracts.pdf (accessed 16 June 2008).
4. Singh AK (2007) Gaps in the quality and potential safety of Biosimilar epoetins in the developing world: an international survey. Abstract S-PO-0412. World Congress of Nephrology, April 21-25 2007 Brazil : Rio de Janeiro. Available at: http://www.wcn2007.org/pdf/WCN2007BooksofAbstracts.pdf (accessed 16 June 2008).
5. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W (2003) Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharmaceutical Research, 20, 1903 1907.
6. Datamonitor (2005) Biogenerics 2005: a new level of complexity. Ref DMHC2140, 25 October 2005.
7. O'Donnell P (2006) Battle of biosimilars. Applied Clinical Trials, Feb 1, Available at: http://www.actmagazine.com/appliedclinicaltrials/article/ articleDetail.jsp?id=306511 (accessed 20 July 2007).
8. Charles SA (2005) SuperGenerics: a better alternative for biogenerics. Drug Discovery Today, 10 (8 533 535.
9. Ben-Maimon CS, Garnick R (2006) Biogenerics at the crossroads. Nature Biotechnology, 24 (3 268 269.
10. Committee for Medicinal Products for Human Use (2005) Guideline on similar biological medicinal products. CHMP/437/04, 2005.
11. Anonymous (2007a) Generic biologics legislation again introduced in congress. Biologic Drug Report. Available at: http://www.biologicdrugreport.com/ News/news-021507.htm (accessed 20 July 2007).
12. Anonymous (2007b) Waxman, Schumer, and Clinton unveil bill to create clear pathway for generic biologic drugs. Available at: http://www.senate.gov/ ∼clinton/news/statements/details.cfm?id=269315 (accessed 20th July 2007).
13. Anonymous (2007c) US maps route for follow-on protein products. Nature Reviews. Drug Discovery, 6, 593.
14. Pharmaceuticals and Medical Devices Agencies (2007) PMDA 1st International Symposium on Biologics. Available at: http://www.pmda.go.jp/ 2007bio-sympo/agenda-e.html (accessed 10 October 2007).
15. Frost and Sullivan (2004) Biogenerics demand to go up in Asia. Express Pharma Pulse October 7, Available at: http://www.expresspharmaonline.com/ 20041007/biogenerics01.shtml (accessed 13 September 2007).
16. Kessler M, Goldsmith D, Schellekens H (2006) Immunogenicity of biopharmaceuticals. Nephrology, Dialysis, Transplantation, 21 (Suppl 5 v13 v16.
17. Macdougall IC (2001) Present and future strategies in the treatment of renal anemia. Nephrology, Dialysis, Transplantation, 16 (Suppl 5 50 55.
18. Cheer SM, Wagstaff AJ (2004) Epoetin beta: a review of its clinical use in the treatment of anemia in patients with cancer. Drugs, 64, 323 346.
19. Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, Schwartz D (2005) Erythropoietin in heart failure. Seminars in Nephrology, 25, 397 403.
20. Besarab A, Reyes CM, Hornberger J (2002) Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases, 40 (3 439 446.
21. Casadevall N, Rossert J (2005) Importance of biologic follow-ons: experience with EPO. Best Practice & Research. Clinical Haematology, 18 (3 381 387.
22. Johnson & Johnson Pharmaceutical Research and Development (2005) Summary of PRCA case reports: update on the actions by Johnson & Johnson Pharmaceutical Research and Development regarding epoetin antibody-positive pure red cell aplasia. Johnson & Johnson Pharmaceutical Research & Development. Available at: http://ww.jnjpharmarnd.com/company_news.html (accessed 11 September 2006).
23. European Generic Medicines Association. Biosimilars. Available at: http://www.egagenerics.com/ega-biosimilars.htm (accessed 25 July 2007).
24. Locatelli F, Roger S (2006) Comparative testing and pharmacovigilance of biosimilars. Nephrology, Dialysis, Transplantation, 21 (Suppl 5 v9 v12.